AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2951811
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 40 micrograms ipratropium bromide and 100 micrograms fenoterol (Duovent)
Trial: 29370572
Drug: Gevokizumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gevokizumab (60 mg every 4 weeks subcutaneously)
Trial: 27881152
Drug: In-bed cycling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-bed cycling sessions (same number, frequency and treatment time as the intervention group)
Trial: 17987065
Drug: Dopamine D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2 receptor (D2-R) density in TS patients with OCD
Trial: 17987065
Drug: Dopamine release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine release (DA(rel)) and serotonin 5-HT2A receptor binding potential (5-HT2A BP) in TS+OCD subjects
Trial: 15717937
Drug: Non-stent therapies
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-stent therapies
Trial: 12876113
Drug: Brief explanation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief explanation to parents regarding the self-limited nature of AOM and the controversy regarding antibiotic prescription.
Trial: 2063503
Drug: Adaptogens treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptogens treatment (0.15 U/kg im insulin, 0.1 mg/kg prednisolone, 0.2 mg/kg dibazol, 250 mg/kg methyluracil daily for 1 week preoperatively)
Trial: 2063503
Drug: Prednisolone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (0.2 mg/kg intravenous administration)
Trial: 15736113
Drug: Methionine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine (0.1 g/kg)
Trial: 15736113
Drug: Homocysteine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homocysteine (0.01 g/kg)
Trial: 15736113
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (NAC) (0.1 g/kg)
Trial: 12952516
Drug: Physiotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy treatment without deep breathing exercises
Trial: 12952516
Drug: Physiotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy treatment with deep breathing exercises (control)
Trial: 2004365
Drug: Hexamethylene bisacetamide
RxNorm normalized name: 1,6-hexamethylene diisocyanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexamethylene bisacetamide administered nasogastrically at 12 g/m2/day
Trial: 2004365
Drug: Hexamethylene bisacetamide
RxNorm normalized name: 1,6-hexamethylene diisocyanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexamethylene bisacetamide administered nasogastrically at 24 g/m2/day
Trial: 2004365
Drug: Hexamethylene bisacetamide
RxNorm normalized name: 1,6-hexamethylene diisocyanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexamethylene bisacetamide administered nasogastrically at 30 g/m2/day
Trial: 2004365
Drug: Hexamethylene bisacetamide
RxNorm normalized name: 1,6-hexamethylene diisocyanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexamethylene bisacetamide administered nasogastrically
Trial: 2004365
Drug: Hexamethylene bisacetamide
RxNorm normalized name: 1,6-hexamethylene diisocyanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexamethylene bisacetamide administered nasogastrically or parenterally
Trial: 6838743
Drug: Sitting position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitting position after extradural injection
Trial: 25483468
Drug: Vaccine efficacy
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine efficacy
Trial: 17242321
Drug: Daily SSRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SSRI use
Trial: 15655141
Drug: Ciclopirox shampoo
RxNorm normalized name: ciclopirox Shampoo Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclopirox shampoo twice weekly
Trial: 15655141
Drug: Ciclopirox shampoo
RxNorm normalized name: ciclopirox Shampoo Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclopirox shampoo once weekly
Trial: 15655141
Drug: Prophylactic ciclopirox
RxNorm normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic ciclopirox once weekly
Trial: 15655141
Drug: Ciclopirox shampoo
RxNorm normalized name: ciclopirox Shampoo Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclopirox shampoo (both treatment and prophylaxis)
Trial: 9527938
Drug: EMLA analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA analgesic cream
Trial: 9527938
Drug: sucrose and
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sucrose and EMLA combination
Trial: 2231096
Drug: Conventional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional steroid therapy, 1000 mg/day for 3 days (group 1)
Trial: 2231096
Drug: Conventional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional steroid therapy, 500 mg/day for 3 days (group 2)
Trial: 2231096
Drug: Conventional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional steroid therapy, 250 mg/day for 3 days (group 3)
Trial: 28185976
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral glibenclamide daily for 10 days, n = 29
Trial: 28185976
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in the same dosage, n = 23
Trial: 22998386
Drug: Essential oil
RxNorm normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential oil mouth rinse (Listerine(®) Coolmint; Johnson & Johnson) used twice per day as an adjunct to mechanical plaque control.
Trial: 22998386
Drug: Placebo mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouth rinse used twice per day as an adjunct to mechanical plaque control.
Trial: 17266173
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin E supplementation (1200 mg/day)
Trial: 11174476
Drug: All dosage
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dosage groups of 17beta-estradiol (Menorest)
Trial: 7653756
Drug: Somatostatin bolus
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin bolus 3.5 micrograms.kg‐1 intravenously plus an infusion of somatostatin 3.5 micrograms.kg‐1.h‐1
Trial: 2671362
Drug: 2% butoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% butoconazole vaginal cream for three days
Trial: 2671362
Drug: 2% miconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% miconazole vaginal cream for seven days
Trial: 21906647
Drug: MF59®-adjuvanted quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59®-adjuvanted quadrivalent influenza vaccine (QIV)
Trial: 21906647
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccines (TIV)
Trial: 19193652
Drug: Lo-Pro GlideScope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lo-Pro GlideScope (LP-G)
Trial: 1961649
Drug: Intensified conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified conventional treatment (n = 44)
Trial: 1961649
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment (n = 52)
Trial: 6119495
Drug: 1% glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% glyceryl trinitrate ointment
Trial: 28651207
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (MCT and CBT)
Trial: 20814331
Drug: Risperidone 1-mg
RxNorm normalized name: risperidone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 1-mg single oral dose
Trial: 18061060
Drug: Test vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test vaccine (inactivated candidate vaccine for JEV)
Trial: 18061060
Drug: Licensed vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed vaccine (mouse‐brain‐derived vaccine)
Trial: 18061060
Drug: Test vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test vaccine
Trial: 18061060
Drug: Licensed vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed vaccine
Trial: 16283239
Drug: Pioglitazone (15‐45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15‐45 mg/day)
Trial: 16283239
Drug: Gliclazide (80‐320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (80‐320 mg/day)
Trial: 16283239
Drug: Metformin (850‐2,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850‐2,550 mg/day)
Trial: 12297475
Drug: Low-dose mitomycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose mitomycin C (MMC) 2-4 mg, 4-6 mg, or 6-8 mg depending on tumor size
Trial: 12297475
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy regimen: 10 mg MMC, 40 mg PI, 300 mg CBP
Trial: 10416522
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone for 14 days
Trial: 2917676
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied betamethasone-17-valerate (0.1% solution and cream) applied twice daily for 7 days
Trial: 2917676
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied betamethasone-17-valerate (0.1% solution and cream) applied twice daily for 14 days
Trial: 31432510
Drug: Balloon catheter
RxNorm normalized name: Paclitaxel coated angioplasty balloon catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon catheter (50-mL for 12 hours)
Trial: 31432510
Drug: Oxytocin (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (low-dose infusion)
Trial: 30599916
Drug: Achillea millefolium
RxNorm normalized name: ACHILLEA MILLEFOLIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achillea millefolium 250 mg/day
Trial: 30599916
Drug: Achillea millefolium
RxNorm normalized name: ACHILLEA MILLEFOLIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achillea millefolium 500 mg/day
Trial: 29231586
Drug: Acupuncture (2-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (2-3 times per week, total of 14 treatments)
Trial: 21546491
Drug: 25% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% human albumin (ALB) administered intravenously at 2 g/kg within 5 hours of stroke onset
Trial: 21546491
Drug: 25% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% human albumin (ALB) administered intravenously at 2 g/kg within 5 hours of stroke onset (among thrombolyzed subjects)
Trial: 16048138
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (10 g orally twice per day for 6 days, then 5 g daily)
Trial: 12351464
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) spray for 4 weeks
Trial: 12351464
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo spray for 4 weeks
Trial: 8010550
Drug: Parenteral magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral magnesium sulfate (MgSO4)
Trial: 8010550
Drug: Combined MgSO4-digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined MgSO4-digoxin therapy
Trial: 2470988
Drug: Cibenzoline 130
RxNorm normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline 130 mg every 12 h
Trial: 2470988
Drug: Cibenzoline 160
RxNorm normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline 160 mg every 12 h
Trial: 2470988
Drug: Quinidine 300
RxNorm normalized name: hydroquinidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine 300 mg every 6 h
Trial: 2470988
Drug: Quinidine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine 400 mg every 6 h
Trial: 11763992
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and furosemide administered in the morning (05:00)
Trial: 11763992
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and furosemide administered in the evening (17:00)
Trial: 15226138
Drug: Revised National
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Revised National Institute on Drug Abuse standard intervention
Trial: 7745464
Drug: Mechanical devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical devices (e.g., graduated leg stockings; external pneumatic calf compression)
Trial: 7745464
Drug: Pharmacological agents
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological agents (e.g., low dose heparin)
Trial: 2643933
Drug: Imipramine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 0.5 mg/kg/d
Trial: 2643933
Drug: Imipramine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 1.5 mg/kg/d
Trial: 2643933
Drug: Imipramine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 3 mg/kg/d
Trial: 1092731
Drug: Naproxen 400
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 400 mg daily
Trial: 19107337
Drug: Duodenal acidification
RxNorm normalized name: Sus scrofa duodenum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duodenal acidification (0.1 N HCl, 20 ml/min for 5 min)
Trial: 19107337
Drug: Pure water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure water infusion (20 ml/min for 5 min)
Trial: 10999643
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment with a focus on maintaining diastolic blood pressure (DBP) above mid- to low 80s.
Trial: 1937790
Drug: Salmonella typhi
RxNorm normalized name: Salmonella Typhi Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmonella typhi Ty21a vaccine (10^9 CFU per dose, three doses)
Trial: 6341435
Drug: Intranasal insufflation
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal insufflation of 50 mg of dry ragweed or timothy grass pollen (antigen challenge)
Trial: 22607553
Drug: Senior centre
RxNorm normalized name: docosahexaenoic acid / phosphatidylserine Oral Capsule [Senior Moment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senior centre group programme (weekly meetings)
Trial: 17054896
Drug: 350‐mm(2) Baerveldt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350‐mm(2) Baerveldt glaucoma implant
Trial: 11932320
Drug: Pegvisomant 20
RxNorm normalized name: pegvisomant 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant 20 mg/d for 7 d
Trial: 11932320
Drug: Octreotide 50
RxNorm normalized name: octreotide 50 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 50 microg thrice daily for 7 d
Trial: 1724116
Drug: Astemizole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (10 mg daily for 2 weeks)
Trial: 22691058
Drug: Adjunctive application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive application of locally delivered minocycline ointment in association with flap surgery (FM)
Trial: 16437375
Drug: Glutamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (30 g/d) for 7 days
Trial: 15215812
Drug: GIK therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK therapy (in diabetic patients)
Trial: 10902791
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy before estrogen treatment
Trial: 8888720
Drug: nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nizatidine 300 mg at night
Trial: 8888720
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg in the morning
Trial: 8888720
Drug: nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nizatidine 300 mg at night and omeprazole 20 mg in the morning
Trial: 3906942
Drug: Indoprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoprofen (400 mg)
Trial: 3305488
Drug: Propranolol (80,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80, 160, or 320 mg/day)
Trial: 3305488
Drug: Chlordiazepoxide (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide (30, 45, or 75 mg/day)
Trial: 28762135
Drug: Everolimus 5
RxNorm normalized name: everolimus 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 5 mg twice daily
Trial: 27582675
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (1 intravitreal bevacizumab injection 1.25 mg + PDT)
Trial: 22544804
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir DF 300 mg once daily for 72 weeks
Trial: 22544804
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 72 weeks
Trial: 10707917
Drug: Prescription NSAIDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription NSAIDs
Trial: 10707917
Drug: Ibuprofen (dosages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (dosages < or =1,200 mg/day)
Trial: 10707917
Drug: Ibuprofen (dosages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (dosages >1,200-<2,400 mg/day)
Trial: 10707917
Drug: Ibuprofen (dosages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (dosages > or =2,400 mg/day)
Trial: 9195347
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg i.v. lidocaine 90 seconds prior to endotracheal intubation
Trial: 1287615
Drug: Cefaclor AF
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor AF (750 mg)
Trial: 1287615
Drug: Cefaclor AF
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor AF (500 mg) alone
Trial: 1287615
Drug: Cefaclor immediate
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor immediate release (500 mg) alone
Trial: 23883636
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (60-minute comprehensive exercise program, twice a week for 3 months)
Trial: 23883636
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + amino acid supplementation (6 g/day for 3 months)
Trial: 23883636
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid supplementation (6 g/day for 3 months)
Trial: 21046171
Drug: Modafinil 100
RxNorm normalized name: modafinil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil 100 mg once daily
Trial: 18029066
Drug: Study vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study vaccine (Group 1)
Trial: 18029066
Drug: Vero cells
RxNorm normalized name: Vero Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vero cells vaccine (Group 2)
Trial: 16271155
Drug: Local steroid
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local steroid treatment (fluticasone) for 4 weeks
Trial: 12114411
Drug: S-1 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 administered once daily at a dose of 50 mg/m2/day for 21 consecutive days
Trial: 12114411
Drug: S-1 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 administered once daily at a dose of 60 mg/m2/day for 21 consecutive days
Trial: 12114411
Drug: Correlation analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation analysis of diarrhea grade with pharmacokinetics